Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Detalles Bibliográficos
Autores principales: Girgis, Suzette, Wang Lin, Shun Xin, Pillarisetti, Kodandaram, Verona, Raluca, Vieyra, Diego, Casneuf, Tineke, Fink, Damien, Miao, Xin, Chen, Yang, Stephenson, Tara, Banerjee, Arnob, Hilder, Brandi W., Russell, Jeffery, Infante, Jeffrey, Elsayed, Yusri, Smit, Jennifer, Goldberg, Jenna D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979748/
https://www.ncbi.nlm.nih.gov/pubmed/36006441
http://dx.doi.org/10.1182/bloodadvances.2022007625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979748/
https://www.ncbi.nlm.nih.gov/pubmed/36006441
http://dx.doi.org/10.1182/bloodadvances.2022007625

Ejemplares similares